Umemoto et al. analyzed 3031 cases of CCA using the FoundationOneTM platform [31] and reported a high frequency of ERBB2 amplification in tumor mutation burden (TMB)-high tumors. This evidence concerns the gene ERBB2 and cholangiocarcinoma.